Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Isavuconazole activity against Aspergillus lentulus, Neosartorya udagawae, and Cryptococcus gattii, emerging fungal pathogens with reduced azole susceptibility.

Literature DB >> 23804388

Isavuconazole activity against Aspergillus lentulus, Neosartorya udagawae, and Cryptococcus gattii, emerging fungal pathogens with reduced azole susceptibility.

K Datta¹, P Rhee, E Byrnes, G Garcia-Effron, D S Perlin, J F Staab, K A Marr.

Abstract

Isavuconazole is an extended-spectrum triazole with in vitro activity against a wide variety of fungal pathogens. Clinical isolates of molds Aspergillus lentulus and Neosartorya udagawae and yeast Cryptococcus gattii VGII (implicated in the outbreak in the Pacific Northwest, North America) exhibit reduced susceptibilities to several azoles but higher susceptibilities to isavuconazole.

Entities: Chemical Species

Mesh：

Substances：

Year: 2013 PMID： 23804388 PMCID： PMC3754638 DOI： 10.1128/JCM.01190-13

Source DB: PubMed Journal: J Clin Microbiol ISSN： 0095-1137 Impact factor: 5.948

45 in total

Review 1. Evaluation of the pharmacokinetics and clinical utility of isavuconazole for treatment of invasive fungal infections.

Authors: Joanne Livermore; William Hope
Journal: Expert Opin Drug Metab Toxicol Date: 2012-04-25 Impact factor: 4.481

Review 2. Editorial: assessing the antimicrobial susceptibility of bacteria obtained from animals.

Authors: Stefan Schwarz; Peter Silley; Shabbir Simjee; Neil Woodford; Engeline van Duijkeren; Alan P Johnson; Wim Gaastra
Journal: J Antimicrob Chemother Date: 2010-02-24 Impact factor: 5.790

3. Role of Aspergillus lentulus 14-α sterol demethylase (Cyp51A) in azole drug susceptibility.

Authors: Emilia Mellado; Laura Alcazar-Fuoli; Manuel Cuenca-Estrella; Juan L Rodriguez-Tudela
Journal: Antimicrob Agents Chemother Date: 2011-09-26 Impact factor: 5.191

4. A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations.

Authors: E Mellado; G Garcia-Effron; L Alcázar-Fuoli; W J G Melchers; P E Verweij; M Cuenca-Estrella; J L Rodríguez-Tudela
Journal: Antimicrob Agents Chemother Date: 2007-03-19 Impact factor: 5.191

5. Mistaken identity: Neosartorya pseudofischeri and its anamorph masquerading as Aspergillus fumigatus.

Authors: S Arunmozhi Balajee; Jennifer Gribskov; Mary Brandt; James Ito; Annette Fothergill; Kieren A Marr
Journal: J Clin Microbiol Date: 2005-12 Impact factor: 5.948

Review 6. Cryptococcus gattii: an emerging fungal pathogen infecting humans and animals.

Authors: Edmond J Byrnes; Karen H Bartlett; John R Perfect; Joseph Heitman
Journal: Microbes Infect Date: 2011-06-01 Impact factor: 2.700

7. Isolation of Aspergillus lentulus in Spain from a critically ill patient with chronic obstructive pulmonary disease.

Authors: Almudena Alhambra; Mercedes Catalán; María Dolores Moragues; Sonia Brena; José Pontón; Juan Carlos Montejo; Amalia del Palacio
Journal: Rev Iberoam Micol Date: 2008-12-31 Impact factor: 1.044

8. The cdr1B efflux transporter is associated with non-cyp51a-mediated itraconazole resistance in Aspergillus fumigatus.

Authors: Marcin G Fraczek; Michael Bromley; Ahmed Buied; Caroline B Moore; Ranjith Rajendran; Riina Rautemaa; Gordon Ramage; David W Denning; Paul Bowyer
Journal: J Antimicrob Chemother Date: 2013-04-10 Impact factor: 5.790

Review 9. Spread of Cryptococcus gattii into Pacific Northwest region of the United States.

Authors: Kausik Datta; Karen H Bartlett; Rebecca Baer; Edmond Byrnes; Eleni Galanis; Joseph Heitman; Linda Hoang; Mira J Leslie; Laura MacDougall; Shelley S Magill; Muhammad G Morshed; Kieren A Marr
Journal: Emerg Infect Dis Date: 2009-08 Impact factor: 6.883

10. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america.

Authors: John R Perfect; William E Dismukes; Francoise Dromer; David L Goldman; John R Graybill; Richard J Hamill; Thomas S Harrison; Robert A Larsen; Olivier Lortholary; Minh-Hong Nguyen; Peter G Pappas; William G Powderly; Nina Singh; Jack D Sobel; Tania C Sorrell
Journal: Clin Infect Dis Date: 2010-02-01 Impact factor: 9.079

14 in total

1. Isavuconazole Is Effective for the Treatment of Experimental Cryptococcal Meningitis.

Authors: Nathan P Wiederhold; Laura Kovanda; Laura K Najvar; Rosie Bocanegra; Marcos Olivo; William R Kirkpatrick; Thomas F Patterson
Journal: Antimicrob Agents Chemother Date: 2016-08-22 Impact factor: 5.191

2. Molecular characterisation and antifungal susceptibility of clinical Cryptococcus deuterogattii (AFLP6/VGII) isolates from Southern Brazil.

Authors: P F Herkert; F Hagen; G L de Oliveira Salvador; R R Gomes; M S Ferreira; V A Vicente; M D Muro; R L Pinheiro; J F Meis; F Queiroz-Telles
Journal: Eur J Clin Microbiol Infect Dis Date: 2016-08-01 Impact factor: 3.267

Review 3. Cryptococcus gattii infections.

Authors: Sharon C-A Chen; Wieland Meyer; Tania C Sorrell
Journal: Clin Microbiol Rev Date: 2014-10 Impact factor: 26.132

4. Phenotypic differences of Cryptococcus molecular types and their implications for virulence in a Drosophila model of infection.

Authors: George R Thompson; Nathaniel Albert; Greg Hodge; Machelle D Wilson; Jane E Sykes; Derek J Bays; Carolina Firacative; Wieland Meyer; Dimitrios P Kontoyiannis
Journal: Infect Immun Date: 2014-05-05 Impact factor: 3.441